866-997-4948(US-Canada Toll Free)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Therapeutic Area

No. of Pages : 44 Pages


Global Markets Direct’s, \'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC). 

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Hepatocellular Carcinoma (HCC).
  • A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Introduction
Global Markets Direct Report Coverage
Metastatic Hepatocellular Carcinoma (HCC) Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Products under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Development
F. Hoffmann-La Roche Ltd.
MedImmune LLC
Active Biotech AB
Alnylam Pharmaceuticals, Inc
Metastatic Hepatocellular Carcinoma (HCC) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG-7686 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dusigitumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tasquinimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-VSP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HLA-A 2402 Restricted Antiangiogenic Peptide Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Drug Profile Updates
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Dormant Products
Metastatic Hepatocellular Carcinoma (HCC) – Product Development Milestones
Featured News & Press Releases
Apr 13, 2010: Endo, Penwest Enter Into Agreement With Barr To Settle Patent Litigation Over Opana ER

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products Under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2013
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
F. Hoffmann-La Roche Ltd., H1 2013
MedImmune LLC, H1 2013
Active Biotech AB, H1 2013
Alnylam Pharmaceuticals, Inc, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Drug Profile Updates
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Dormant Products

List of Chart


Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2013
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *